At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 137 enrolled
Drug / intervention
DS-1062adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum Based Chemotherapy (TROPION-Lung05)
In Brief
A Phase 2 clinical trial evaluating DS-1062a for Non-small Cell Lung Cancer. Completed, enrolled 137 participants across 84 sites in 10 countries.
Detailed Summary
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesFrance, Germany, Hungary, Italy, Japan, Netherlands, South Korea, Spain, Taiwan, United States
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartMar 2021
Primary CompletionMar 2023
Study CompletionFeb 2026
TodayJul 2026
First PostedJul 23, 2020
Enrollment StartMar 30, 2021
Primary CompletionMar 10, 2023
Study CompletionFeb 4, 2026
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 5.9 years ago
Interventions
DS-1062adrug
DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks